שווי פעילות לרווח לפני ריבית, מסים ופחת Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics (ARQT) is implementing cloud-based AI to automate data collection in dermatological research. Demand for skin treatments remains stable, rendering the business virtually independent of macroeconomic trends. However, promotion costs for Zoryve and insurance risks are weighing on profits. The current EV/EBITDA multiple on the GURU.Markets chart shows that the indicator stands at 90.55.

The scaling of ZORYVE therapy commercialization is directly reflected in the EV/EBITDA chart, allowing for an assessment of the business's market value inclusive of net debt. This indicator compares the total cost of acquiring the asset with operating profit before depreciation and amortization, determining the investment payback period and the level of financial stability for Arcutis Biotherapeutics (ARQT) during periods of volatility.